首页> 外文期刊>International Journal of Pharmaceutics >Preparation of dual crosslinked alginate-chitosan blend gel beads and in vitro controlled release in oral site-specific drug delivery system.
【24h】

Preparation of dual crosslinked alginate-chitosan blend gel beads and in vitro controlled release in oral site-specific drug delivery system.

机译:双重交联的藻酸盐-壳聚糖共混凝胶珠的制备以及在口服部位特异性药物递送系统中的体外控释。

获取原文
获取原文并翻译 | 示例
           

摘要

Alginate-chitosan (ALG-CS) blend gel beads were prepared based on Ca2+ or dual crosslinking with various proportions of alginate and chitosan. The homogeneous solution of alginate and chitosan was dripped into the solution of calcium chloride; the resultant Ca2+ single crosslinked beads were dipped in the solution of sodium sulfate sequentially to prepare dual crosslinked beads. The dual crosslinkage effectively promoted the stability of beads under gastrointestinal tract conditions. The sustained release profiles of single and dual crosslinked gel beads loaded bovine serum albumin (BSA), a model protein drug, were investigated in simulated gastric fluid (SGF), simulated intestinal fluid (SIF) and simulated colonic fluid (SCF). In SGF, compared to Ca2+ single crosslinked beads, from which BSA released fast and the cumulative drug release percentages were about 80% of all formations in 4 h, the BSA total release from dual crosslinked gel beads was no more than 3% in 8 h. In SIF and SCF, Ca2+ single crosslinked beads were disrupted soon associating with the fast drug release. As to the dual crosslinked beads, the BSA total release from the ALG-CS mass ratio 9:1 (81.24%) was higher than that of 7:3 and 5:5 (less than 60%) in 8 h in SIF; the BSA release from all beads was much faster in SCF than in SIF. The dual crosslinked beads incubated in gastrointestinal tract conditions, the BSA cumulative release of ALG-CS mass ratios 9:1, 7:3 and 5:5 were respectively 2.35, 1.96, 1.76% (in SGF 4 h), 82.86, 78.83, 52.91% (in SIF 3 h) and 97.84, 96.81, 87.26% (in SCF 3 h), which suggested that the dual crosslinked beads have potential small intestine or colon site-specific drug delivery property.
机译:基于Ca 2+或具有各种比例的藻酸盐和壳聚糖的双交联制备藻酸盐-壳聚糖(ALG-CS)共混凝胶珠。将藻酸盐和壳聚糖的均匀溶液滴入氯化钙溶液中;将所得的Ca 2+单交联珠粒依次浸入硫酸钠溶液中以制备双交联珠粒。双重交联在胃肠道条件下有效地促进了珠的稳定性。在模拟胃液(SGF),模拟肠液(SIF)和模拟结肠液(SCF)中研究了装载有牛血清白蛋白(一种模型蛋白药物)的单和双交联凝胶珠的持续释放特性。在SGF中,与Ca2 +单交联珠相比,BSA在4小时内从中快速释放并且累积药物释放百分比约为所有形式的80%,而双交联凝胶珠在8 h中从BSA的总释放中不超过3% 。在SIF和SCF中,与快速药物释放相关的Ca2 +单交联珠很快被破坏。对于双交联珠,在SIF中8小时BSA从ALG-CS质量比9:1(81.24%)的总释放高于7:3和5:5(小于60%)。 SCF中所有珠粒的BSA释放都比SIF中快得多。在胃肠道条件下孵育的双交联珠粒中,BSA累积释放的ALG-CS质量比为9:1、7:3和5:5,分别为2.35、1.96、1.76%(在SGF中4 h),82.86、78.83, 52.91%(在SIF 3小时内)和97.84、96.81、87.26%(在SCF 3小时内),这表明双交联珠具有潜在的小肠或结肠部位特异性药物递送特性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号